Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.

Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi - 1 Jan 2000

Miron L, Negură L, Peptanariu D, Marinca M

Abstract excerpt

UNLABELLED: Single nucleotide polymorphisms (SNPs) of the CYP19A1 gene have shown the ability to modify its activity, but no association has been established with aromatase inhibitor (AI) efficiency in hormone receptor positive breast cancer (BC). MATERIAL AND METHODS: The study included blood samples from 53 patients (p) with BC and 1 control (male DNA); 22p. (investigational group) were administered an Al and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Aromatase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aromatase Inhibitors

Share to Incidence

Share to Patient Selection

Share to Predictive Value of Tests

Share to Recurrence

Share to Survival Rate

Source

Identifiers

PMID: 23700878

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.PMID 23700878Read ↗

Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.Semantic proximity Read ↗

Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.Semantic proximity Read ↗

Breast Cancer Susceptibility: Meta-Analysis of Cytochrome P450 2C19 (CYP2C19) and Estrogen Receptor-1 (ESR1) Genetic Variants.Semantic proximity Read ↗

Significance of the Estrogen Hormone and Single Nucleotide Polymorphisms in the Progression of Breast Cancer among Female.Semantic proximity Read ↗

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.Semantic proximity Read ↗

Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.Semantic proximity Read ↗

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.Semantic proximity Read ↗

CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.Semantic proximity Read ↗

The impact of CYP19A1 variants and haplotypes on breast cancer risk, clinicopathological features and prognosis.Semantic proximity Read ↗

Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.Semantic proximity Read ↗

S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.Semantic proximity Read ↗

The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.